Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 17/20 | 0.49 |
| ▸ | GIPR | P48546 | 3/20 | 0.45 |
| ▸ | VIPR2 | P41587 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.45 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.45 |
| ▸ | DUSP2 | Q05923 | 1/20 | 0.45 |
| ▸ | GLP1R | P43220 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3467312 | 1.00 | GCGR (0.49) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL12212650 | 0.91 | GCGR (0.50) | GCGRGIPRHSP90AA1 | |
| SCHEMBL2518884 | 0.90 | GCGR (0.49) | GCGRHSP90AA1 | |
| SCHEMBL2520140 | 0.90 | GCGR (0.57) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL2518883 | 0.88 | GCGR (0.47) | GCGRGIPRHSP90AA1 | |
| SCHEMBL2192992 | 0.85 | GCGR (0.47) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL13344427 | 0.84 | GCGR (0.53) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL2522279 | 0.82 | GCGR (0.47) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL2669859 | 0.82 | GCGR (0.48) | GCGRGIPRVIPR2CYP1A2CYP3A4 | |
| SCHEMBL2518306 | 0.81 | GCGR (0.55) | GCGRGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445538-B2 | Glucagon receptor antagonist compounds | MERCK SHARP & DOHME CORP. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445538-B2 | Glucagon receptor antagonist compounds | MERCK SHARP & DOHME CORP. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110251248-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2011-10-13 | — | — | US | disclosed |
| US-20110251248-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251248-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS | GLP1R, GCGR, GPR119 | GCGR 2/4885GIPR 4/4885VIPR2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.